Treatment of Rheumatoid Arthritis With Roxithromycin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00439062|
Recruitment Status : Completed
First Posted : February 22, 2007
Last Update Posted : February 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: Roxithromycin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Treatment of Rheumatoid Arthritis With Roxithromycin|
|Study Start Date :||June 2006|
|Study Completion Date :||June 2006|
- The primary efficacy variable was the percentage of patients who had a 20 percent improvement according to American College of Rheumatology (ACR) criteria (an ACR 20 response) at six months.
- Secondary outcome measures were 50 percent improvement and 70 percent improvement according to ACR criteria (an ACR 50 response and an ACR 70 response, respectively).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00439062
|Nazilli State Hospital|
|Nazilli, Aydin, Turkey, 09800|
|Principal Investigator:||Mesut Ogrendik, MD||Nazilli State Hospital|